Avian influenza is an infection caused by avian (bird) influenza (flu) viruses. These influenza viruses occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. However, avian influenza is very contagious among birds and can make some domesticated birds, including chickens, ducks, and turkeys, very sick and kill them.
Zoonotic diseases are diseases or infections which are naturally transmissible from animals to humans, as defined in the OIE Terrestrial Animal Health Code.
Viruses can't live without us -- literally. As obligate parasites, viruses need a host cell to survive and grow. Scientists are exploiting this characteristic by developing therapeutics that close off pathways necessary for viral infection, essentially stopping pathogens in their tracks.
Diverse antibodies induced in humans by vaccination with an avian influenza virus vaccine may offer broader, more durable protection against multiple strains of influenza than today's vaccines typically provide, according to a study led by Florian Krammer, PhD, Assistant Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, and Patrick Wilson, PhD, Associate Professor in the Department of Medicine at the University of Chicago.
Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.
In response to the global call for urgently needed resources to fight the spread of the Zika virus, RB is announcing a Zika Relief Package of $1 million USD consisting of both cash and product donations that will be made available to health authorities and international NGOs battling the outbreak.
Scientists at Imperial College London have discovered how flu viruses 'hijack' cell machinery when they infect the body. The findings, published in the journal Nature, may pave the way for more effective antiviral treatments for pandemics and for seasonal flu, which infects over 800 million people worldwide every year.
The avian influenza A (H7N9) virus has been a major concern since the first outbreak in China in 2013. Due to its high rate of lethality and pandemic potential, H7N9 vaccine development has become a priority for public health officials. However, candidate vaccines have failed to elicit the strong immune responses necessary to protect from infection.
Vaccines to protect against an avian influenza pandemic as well as seasonal flu may be mass produced more quickly and efficiently using technology described today (Sept. 2) by researchers at the University of Wisconsin-Madison in the journal Nature Communications.
Scientists in the Center for Infection and Immunity at Columbia University's Mailman School of Public Health have discovered a new virus in seals that is the closest known relative of the human hepatitis A virus. The finding provides new clues on the emergence of hepatitis A.
Hoaglund Enterprises, Inc.,dba Asset Equipment Appraisals & Brokerage, a leading Nationally Certified Appraisal company is pleased to announce that they have been awarded a contract to appraise Avian Flu affected equipment that cannot be disinfected on infected farms by the USDA.
In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune response of inactivated influenza vaccines) increased the immune responses to two doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest amount of antibody response, according to a study in the July 21 issue of JAMA.
A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain.
A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people.
A simple and effective portable tool to predict avian flu outbreaks on farms has been created by University of Guelph researchers.
Highly pathogenic avian influenza (HPAI) H5 viruses of Eurasian origin continue to circulate and evolve in North American wild birds.
Adults over the age of 30 only catch flu about twice a decade, a new study suggests. Flu-like illness can be caused by many pathogens, making it difficult to assess how often people are infected by influenza.
Since 2003, the H5N1 influenza virus, more commonly known as the bird flu, has been responsible for the deaths of millions of chickens and ducks and has infected more than 650 people, leading to a 60 percent mortality rate for the latter. Luckily, this virus has yet to achieve human-to-human transmission, but a small number of mutations could change that, resulting in a pandemic.
The Food and Agriculture Organization of the United Nations (FAO) has appointed SIB Swiss Institute of Bioinformatics as the FAO Reference Centre for bioinformatics.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.
Roche today announced that the U.S. Food and Drug Administration has provided an Emergency Use Authorization (EUA) for the LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, such as individuals traveling from West Africa.